Coffee reduces ovarian cancer: Caffeine may reduce the risk of ovarian cancer, particularly in women who do not use hormones, according to the March 1 journal CANCER, which revealed findings of Shelley S. Tworoger, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, et al. "The potential reduction in risk with higher caffeine intake appeared to be strongest for women who had never used oral contraceptives or postmenopausal hormones," an abstract of the study notes. Researchers also found cigarette smoking may only increase the risk for mucinous ovarian tumors, and alcohol intake is not associated with risk. Researchers gleaned data from questionnaires from the Nurses' Health Study, examining associations between caffeine or alcohol and ovarian cancer risk among 80,253 women between 1976 and 2004. Tworoger, et al. claim more research is needed...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.